MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $51.2M (cash outflow) rose 100.4% year over year, ahead of the +92.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +71.8% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +100.4% holds above the trailing-twelve-month pace of +92.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (138.61M) USD
- Year-over-year change
- -74.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (138.61M) | -74.2% |
| FY2024 | 2024-12-31 | (79.59M) | -51.7% |
| FY2023 | 2023-12-31 | (52.47M) | -92.0% |
| FY2022 | 2022-12-31 | (27.32M) | — |
Free Cash Flow vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 free cash flow of $164.26M is the 4th largest of the 11 companies compared; the peer median is $57.29M.
- Its year-over-year change of +92.8% is the 2nd highest of 9, against a peer median of +13.6%.
- Over three fiscal years its annual growth of +71.8% compares with a peer median of +28.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.78B | — | +718.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M | -3.0% | +21.4% | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $190.28M | +67.0% | +37.9% | — |
| LTM Mar 2026 | $164.26M | +92.8% | +71.8% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $80.71M | +16.8% | +192.3% | 403.5% |
| LTM Mar 2026 | $62.86M | +14.6% | +34.8% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $51.71M | — | +134.7% | — |
| LTM Mar 2026 | $46.51M | +12.6% | +18.5% | — | |
| LTM Mar 2026 | $41.95M | -15.4% | -12.2% | 589.1% | |
| LTM Dec 2025 | $34.08M | -4.3% | +17.2% | — | |
| LTM Mar 2026 | $12M | +119.4% | -49.4% | 9.8% | |
| Peer median (excluding MPLT) | $57.29M | +13.6% | +28.1% | 403.5% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Other Non-Cash Items | 1.14M | 1.11M | 1.13M | 35.27M |
| Operating Cash Flow | (26.58M) | (52.01M) | (78.82M) | (138.14M) |
| Capital Expenditures | (746K) | (462K) | (770K) | (473K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (125.02M) | (408.23M) |
| Sales of Investments | 0 | 0 | 45M | 85.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (746K) | (462K) | (80.79M) | (323.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.17M | 104.57M | 120.25M | 474.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33.18M | 104.57M | (2.19M) | (5.02M) |
| Financing Cash Flow | 33.17M | 104.57M | 118.06M | 469.82M |
| Effect of Forex Changes | 21.81M | 0 | 27K | 0 |
| Net Change in Cash | 27.67M | 52.1M | (41.52M) | 8.48M |
| Free Cash Flow | (27.32M) | (52.47M) | (79.59M) | (138.61M) |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.